Fadraciclib

DRUG4 trials

Sponsors

Gustave Roussy, Cancer Campus, Grand Paris, Cyclacel Pharmaceuticals, Inc.

Conditions

HealthyLeukemiaLymphomaMyelodysplastic Syndrome(MDS)Pediatric CancerSolid Tumor, Adult

Early Phase 1

Absorption, Metabolism, and Excretion of CYC065 in Healthy Male Subjects

CompletedNCT05817890

Cyclacel Pharmaceuticals, Inc.Healthy

Start: 2023-03-03End: 2024-05-22Updated: 2024-09-19

Phase 1

European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors

RecruitingNCT02813135

Gustave Roussy, Cancer Campus, Grand ParisPediatric Cancer

Start: 2016-08-03End: 2031-02-01Target: 472Updated: 2026-01-16

A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma

RecruitingNCT04983810

Cyclacel Pharmaceuticals, Inc.Lymphoma, Solid Tumor, Adult

Start: 2021-07-12End: 2025-06-30Target: 330Updated: 2024-01-25

A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

SuspendedNCT05168904

Cyclacel Pharmaceuticals, Inc.Leukemia, Myelodysplastic Syndrome(MDS)

Start: 2021-10-22End: 2024-12-31Target: 210Updated: 2024-02-08

Related Papers

A phase 1 study evaluating the safety, pharmacokinetics, and efficacy of fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma.

Journal of Clinical Oncology2024-06-014 citations

Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial

The Oncologist2024-05-306 citations

The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies

Cancer Discovery2022-03-16143 citations

INFORM2 NivEnt: The first trial of the INFORM2 biomarker driven phase I/II trial series: the combination of nivolumab and entinostat in children and adolescents with refractory high-risk malignancies

BMC Cancer2020-06-0535 citations

AcSé-ESMART: European Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in Children and Adolescents–Arm D: Olaparib and irinotecan.

Journal of Clinical Oncology2019-05-208 citations

Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.

Journal of Clinical Oncology2019-05-205 citations

EAPH-05. MOLECULAR PROFILING AND IDENTIFICATION OF TARGETED THERAPIES FOR CHILDREN AND YOUNG ADULTS WITH PRIMARY CENTRAL NERVOUS SYSTEM TUMOURS IN THE UNITED KINGDOM

Neuro-Oncology2018-06-01

Abstract CT004: European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study

Cancer Research2017-07-019 citations